Notch is out — your watchlist beside the MacBook notch, synced with this account.
Learn more ↗We use cookies and similar technologies for analytics, to understand how the site is used. You can accept or decline non-essential cookies. See our Privacy Policy.
Daily historical data with per-account defaults
Filings, earnings, research, and institutional changes — newest first
EPS 6,566 · 매출 4672.5억. 세부 수치와 가이던스는 원문에서 확인하세요.
한미사이언스의 대량보유 변동 보고
상무이사 신해곤의 자기 주식 변동 (+34주)
Consensus vs. actual, and revenue trend
Rating & price-target changes
Hanmi Pharmaceutical is a domestic pharmaceutical company that researches, develops, produces, and sells prescription drugs (ETC) and over-the-counter drugs (OTC). The company primarily supplies pharmaceuticals for various disease areas, including treatments for chronic diseases such as hypertension, diabetes, and hyperlipidemia, as well as oncology drugs and orphan drugs. Hanmi Pharmaceutical focuses its R&D efforts on developing innovative new drugs, thereby securing its competitiveness in both domestic and international markets.
Korean business-press RSS, supplemented with portal search and English Yahoo Finance headlines.
Roche outlays $2.3bn for Hanmi’s non-GLP-1 obesity candidate
Roche commits to lean-mass preservation with Hanmi obesity deal
Hanmi Pharm Signs Exclusive Licensing Deal with Genentech for Novel Obesity Therapy
How Lilly is defending its GLP empire
Eli Lilly Expands Beyond Obesity With US$4b Vaccine And Genetic Bets
Eli Lilly Broadens Beyond Obesity Drugs With Vaccine And Genetic Bets
| Quarter | Date | Time | EPS est. | EPS actual | Surprise | Rev. est. | Rev. actual | Status |
|---|---|---|---|---|---|---|---|---|
| FY2026 Q2 | 2026. 08. 14. | Time TBD | — | ₩6,566 | — | — | ₩467.25B | Reported |
| FY2026 Q1 | 2026. 05. 15. | Time TBD | — | ₩3,586 | — | — | ₩392.93B | Reported |
| FY2025 Q3 | 2025. 11. 14. | Time TBD | — | ₩3,165 | — | — | ₩362.35B | Reported |
| FY2025 Q2 | 2025. 08. 14. | Time TBD | — | ₩3,052 | — | — | ₩361.28B | Reported |
| Date | Firm | Analyst | Action | Rating change | Price target | Report |
|---|---|---|---|---|---|---|
| 2026. 08. 25. | DS투자증권 | — | Maintain | — → — | — | 비만 Next generation: 근육 보존제 UCN-2 |
| 2026. 08. 25. | 하나증권 | — | Maintain | — → — | — | 초기 개발 물질을 선급금 8%, 3조원 규모로 .. |
| 2026. 08. 25. | 유안타증권 | — | Maintain | — → — | — | HM17321 가치 증명 |
| 2026. 08. 25. | 미래에셋증권 | — | Maintain | — → — | — | 릴리와 노보를 잡을 무기, 로슈는 한미에서 .. |
| 2026. 08. 25. | IBK투자증권 | — | Maintain | — → — | — | 3개월 만에 두 번째 조 단위 계약 |
| 2026. 08. 25. | 키움증권 | — | Maintain | — → — | — | Hanmi is BACK !! |
As of FY2026Q2 · Source: SEC/DART + price data
Auto-aggregated from recent research reports (per-report average)
